It is our understanding that as one of the first gene therapy BLAs founded on a surrogate endpoint the advisory committee will primarily relate to the totality of evidence supporting the conclusion that the SRP 9001 dystrophin is reasonably likely to predict clinical benefit the standard for accelerated approval said Doug Ingram  president and chief executive officer Sarepta